Victoria L. Buchanan

Victoria L. Buchanan

Auto-generated profile, based on publicly available information

Victoria L. Buchanan

Department of Epidemiology, Border Health Research Center, School of Public Health, Brownsville Regional Campus, The University of Texas Health Science Center at Houston, Brownsville, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Environmental Health Perspectives
Verified
Journal Article
Closed access
CAChristy L Avery
Christy L Avery
AHAnnie Green Howard
Annie Green Howard
ABAnna F. Ballou
Anna F. Ballou
VBVictoria L. Buchanan
Victoria L. Buchanan
JCJason M. Collins
Jason M. Collins
PGPenny Gordon-Larsen
Penny Gordon-Larsen

30 December 2020 in Pediatric Obesity
Verified
Journal Article
Closed access
PDF file
VBVictoria L Buchanan
Victoria L Buchanan
YWYujie Wang
Yujie Wang
EBEstela Blanco
Estela Blanco
MGMariaelisa Graff
Mariaelisa Graff
CACecilia Albala
Cecilia Albala
KNKari North
Kari North

7 April 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
XZXinruo Zhang
Xinruo Zhang
ASAshley W. Scadden
Ashley W. Scadden
AMAmarnath Marthi
Amarnath Marthi
VBVictoria L. Buchanan
Victoria L. Buchanan
YQYishu Qu
Yishu Qu
MSMaggie Stanislawski
Maggie Stanislawski
Key Points: We aimed to elucidate potential methylation, proteomic, and metabolomic mechanisms by which APOL1 variants may be linked to kidney disease. We report distinct methylation profiling between APOL1 risk allele carriers and noncarriers, many near APOL gene family. We report higher APOL1 protein and lower C18:1 cholesteryl ester in two risk allele carriers. Background: The APOL1 high-risk haplotype has been associated with CKD and the deterioration of kidney function, particularly in populations with West African ancestry. However, the mechanisms by which APOL1 risk variants increase the risk for kidney disease and its progression have not been fully elucidated. Methods: We compared methylation ( N =3191; 715 [22%] carriers), proteomic ( N =1240; 169 [14%] carriers), and metabolomic ( N =6309; 674 [11%] carriers) profiles in African and Hispanic/Latino carriers of two APOL1 high-risk alleles (G1/G1, G2/G2, G1/G2) and noncarriers (G0/G0), excluding heterozygotes (G0/G1, G0/G2), from the Population Architecture using Genomics and Epidemiology Consortium and UK Biobank. In each study, the associations between the APOL1 high-risk haplotype and up to 722,719 cytosine-phosphate-guanine (CpG) sites, 2923 proteins, or 836 metabolites were estimated using covariate-adjusted linear regression models, followed by fixed-effects sample size–weighted meta-analyses. Results: Significant associations were observed between APOL1 high-risk haplotype and methylation at 52 CpG sites, with 48 located on chromosome 22 and 18 in the vicinity of APOL1–4 and MYH9 . All significant CpG sites near APOL2 were hypomethylated, whereas those near APOL3 and APOL4 were hypermethylated. APOL1 -associated CpG sites were also identified in genes involved in ion transport and mitochondrial stress pathways. Sensitivity analyses indicated consistent yet attenuated effects among heterozygotes, supporting an additive effect of APOL1 risk alleles. Further analyses of the 52 CpG sites identified two near APOL4 exhibiting G1-specific effects, eight associated with CKD but none with eGFR, and three showing heterogeneity by CKD status. In addition, carrying two APOL1 risk alleles was associated with higher plasma APOL1 protein ( β =1.12, P FDR = 2.26e-70) and lower C18:1 cholesteryl ester metabolite (Z=−4.50, P FDR = 4.83e-3). Conclusions: Our results demonstrate differential methylation, proteomic, and metabolomic profiles associated with APOL1 high-risk haplotypes.


1 August 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
DKDaeeun Kim
Daeeun Kim
HPHannah G. Polikowsky
Hannah G. Polikowsky
HHHeather M. Highland
Heather M. Highland
HCHung-Hsin Chen
Hung-Hsin Chen
WZWanying Zhu
Wanying Zhu
MGMisa Graff
Misa Graff
BACKGROUND: While GWAS (genome-wide association studies) have identified over 1000 obesity-associated loci, their functional impact on gene expression remains unclear. Moreover, many studies have not fully captured the genetic architecture of obesity in high-risk populations or considered the complexity of adiposity beyond traditional measures. To address these gaps, this study explores the genetic and transcriptomic pathways of obesity using diverse obesity phenotypes in a high-risk population. METHODS: We analyzed genomic and whole-blood transcriptomic data from the CCHC (Cameron County Hispanic Cohort), performing GWAS on 13 obesity-related traits. Differential expression analysis was conducted for genes near GWAS-identified single nucleotide polymorphisms ( P <5×10 −6 ) followed by expression quantitative trait loci mapping and GWAS-expression quantitative trait loci colocalization. RESULTS: GWAS identified 486 trait associations, including 6 genome-wide significant ( P <5×10 −8 ) loci, with 3 novel signals linked to abdominal subcutaneous adipose tissue, body fat percentage, and waist circumference. Among 3024 genes near these loci, 60 showed differential expression. Further expression quantitative trait loci analysis suggested 2 single nucleotide polymorphism-gene-trait relationships: rs543314376- MAPK11 , associated with subcutaneous adipose tissue volume in females, and rs963018484- PER1 , linked to body mass index in females. Both genes play key roles in obesity-related pathways, including inflammation and circadian rhythm regulation. CONCLUSIONS: This integrative genomic-transcriptomic analysis uncovers 2 novel candidate genes for obesity and underscores the critical need for involving all populations and comprehensive adiposity measures in obesity research. By expanding beyond body mass index in a Hispanic/Latino population, we move closer to a deeper and more inclusive understanding of obesity’s genetic architecture.

11 September 2026 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
JLJoshua M. Landman
Joshua M. Landman
HHHeather M. Highland
Heather M. Highland
APAndrew S. Perry
Andrew S. Perry
AHAnnie Green Howard
Annie Green Howard
QSQuanhu Sheng
Quanhu Sheng
RSRavi V. Shah
Ravi V. Shah
While the earliest pathological signs of cardiovascular–kidney–metabolic disease (CKMD) emerge before age 20, current adult-based risk thresholds fail to identify a substantial fraction of children at high risk. With increasing childhood obesity, early, sensitive detection of CKMD risk is critical to timely intervention. We linked 25 CKMD phenotypes spanning liver, adipose, vascular and dysglycaemia traits to the circulating proteome in 273 Hispanic or Latino children and adolescents (13.1 ± 2.7 years; 53% female). Here we show that proteome signatures of CKMD in children are strongly associated with clinical CKMD outcomes in adults. In 685 adults from the same community and 28,256 adults from UK Biobank, we observe high concordance between the paediatric and adult CKMD phenotype–proteome relationships, related to pancreatic beta-cell health and insulin sensitivity, liver homeostasis, inflammation and cholesterol metabolism. Many proteins linked to paediatric CKMD were modifiable with glucagon-like peptide-1 receptor agonist therapy in adults and are linked to genetic liability to CKMD. These findings support an early origin of CKMD disease liability embedded in the human proteome in children, underscoring the value of precision prevention to forestall metabolic disease long before its clinical manifestation.